Metacrine Inc. (MTCR): Price and Financial Metrics
MTCR Price/Volume Stats
| Current price | $0.58 | 52-week high | $0.59 |
| Prev. close | $0.59 | 52-week low | $0.30 |
| Day low | $0.58 | Volume | 83,800 |
| Day high | $0.59 | Avg. volume | 225,834 |
| 50-day MA | $0.56 | Dividend yield | N/A |
| 200-day MA | $0.49 | Market Cap | 24.75M |
MTCR Stock Price Chart Interactive Chart >
Metacrine Inc. (MTCR) Company Bio
Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.
Latest MTCR News From Around the Web
Below are the latest news stories about METACRINE INC that investors may wish to consider to help them evaluate MTCR as an investment opportunity.
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger AgreementLA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www |
Metacrine Reports Third-Quarter 2022 ResultsSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical d |
Why Is Equillium (EQ) Stock Soaring 20% Today?Biotech firm Equillium is on the move as it released positive data for a lupus therapeutic, though EQ stock has a tough road ahead. |
Equillium Buys Inflammatory Bowel Disease Player In All-Stock DealEquillium Inc (NASDAQ: EQ) has agreed to acquire Metacrine Inc (NASDAQ: MTCR) in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. Earlier this year, Metacrine axed 50% of its workforce. Through the acquisition, Equillium adds Metacrine's farnesoid X receptor platform, including lead molecule MET642 for inflammatory bowel diseases. Equillium will be seeking |
Equillium to Acquire Metacrine in All-Stock TransactionLA JOLLA, Calif., September 06, 2022--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium’s balance sheet at closing, which is expected to extend the company’s cash runway into 2024. The transaction has been approved by the boards of directors of bot |
MTCR Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 1.35% |
| 1-year | 24.97% |
| 3-year | -94.34% |
| 5-year | N/A |
| YTD | 29.49% |
| 2022 | -33.57% |
| 2021 | -91.42% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...